OBJECTIVE: We evaluated the therapeutic effectiveness of a new, orally active epoxyeicosatrienoic acid analog (EET-A) in rats with angiotensin II (ANG II)-dependent malignant hypertension. METHODS: Malignant hypertension was induced in Cyp1a1-Ren-2 transgenic rats by activation of the renin gene using indole-3-carbinol (I3C), a natural xenobiotic. EET-A treatment was started either simultaneously with I3C induction process (early treatment) or 10 days later during established hypertension (late treatment). Blood pressure (BP) (radiotelemetry), indices of renal and cardiac injury, and plasma and kidney levels of the components of the renin-angiotensin system (RAS) were determined. RESULTS: In I3C-induced hypertensive rats, early EET-A treatment attenuated BP increase (to 175 ± 3 versus 193 ± 4 mmHg, P < 0.05, on day 13), reduced albuminuria (15 ± 1 versus 28 ± 2 mg/24 h, P < 0.05), and cardiac hypertrophy as compared with untreated I3C-induced rats. This was associated with suppression of plasma and kidney ANG II levels (48 ± 6 versus 106 ± 9 and 122 ± 19 versus 346 ± 11 fmol ml or g, respectively, P < 0.05) and increases in plasma and kidney angiotensin (1-7) concentrations (84 ± 9 versus 37 ± 6 and 199 ± 12 versus 68 ± 9 fmol/ml or g, respectively, P < 0.05). Remarkably, late EET-A treatment did not lower BP or improve renal and cardiac injury; indices of RAS activity were not affected. CONCLUSION: The new, orally active EET-A attenuated the development of experimental ANG II-dependent malignant hypertension, likely via suppression of the hypertensiogenic axis and augmentation of the vasodilatory/natriuretic axis of RAS.

Center for Experimental Medicine Institute for Clinical and Experimental Medicine bDepartment of Pathophysiology 2nd Faculty of Medicine Charles University cDepartment of Developmental Cardiology Institute of Physiology Academy of Sciences of the Czech Republic Prague Czech Republic dSection of Nephrology Medical Policlinic Department of Medicine University of Bonn Bonn Germany eDepartment of Renal and Body Fluid Physiology Mossakowski Medical Research Centre Polish Academy of Science Warsaw Poland fDepartment of Biochemistry University of Texas Southwestern Medical Center Dallas Texas gDepartment of Pharmacology and Toxicology Medical College of Wisconsin Milwaukee Wisconsin USA

Zobrazit více v PubMed

Volhard F, Fahr T. Die Brightsche Nierenkrankeit: Klinik, Pathologie und Atlas. Berlin: Springer; 1914.

Byrom FB. The hypertensive vascular crisis. London: William Heinemann Medical Books Ltd; 1969.

Giese J. The renin–angiotensin system and the pathogenesis of vascular disease in malignant hypertension. Clin Sci Mol Med. 1976;51:19–21. PubMed

Kawazo N, Eto T, Abe I, Takishita S, Ueno M, Kobayashi K, et al. Pathophysiology in malignant hypertension: with special reference to the renin–angiotensin system. Clin Cardiol. 1987;10:513–518. PubMed

Laragh JH. Laragh’s lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001;14:186–194. PubMed

Van den Born BJ, Koopmans RP, van Montfrans GA. The renin–angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. Am J Hypertens. 2007;20:900–906. PubMed

Guerin C, Gonthier R, Berthoux FC. Long-term prognosis in malignant or accelerated hypertension. Nephrol Dial Transplant. 1988;3:33–37. PubMed

Lane DA, Lip GYH, Beevers DG. Improving survival of malignant hypertension patients over 40 years. Am J Hypertens. 2009;22:1199–1204. PubMed

Shantsila A, Lane D, Beevers DG, Lip GYH. Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension: the West Birmingham Malignant Hypertension study. J Hypertens. 2012;30:974–979. PubMed

Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M, et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31:1925–1938. PubMed

Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED., Jr Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med. 1972;52:633–652. PubMed

Laragh JH, Sealey JE, Atlas SA. The renin system for understanding human hypertension: evidence for blood pressure control by a bipolar vasoconstriction-volume mechanism. Prorenin as a determinant of renin secretion. Clin Exp Hypertens. 1982;4:2303–2337. PubMed

Laragh JH, Sealey JE. Renin system understanding for analysis and treatment of hypertensive patients: a means to quantify the vasoconstrictor elements, diagnose curable renal and adrenal causes, assess risk of cardiovascular morbidity, and find the best-fit drug regimen. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. New York, NY: Raven Press, Publishers; 1990. pp. 1813–1836.

Kincaid-Smith P. Malignant hypertension. J Hypertens. 1991;9:893–899. PubMed

Fleming S. Malignant hypertension – the role of the paracrine renin–angiotensin system. J Pathol. 2000;192:135–139. PubMed

Fleming I. The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease. Pharmacol Rev. 2014;66:1106–1140. PubMed

Imig JD. Epoxyeicosatrienoic acids, hypertension, and kidney injury. Hypertension. 2015;65:476–482. PubMed PMC

Elmarakby AA. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease. Am J Physiol. 2012;302:R321–R330. PubMed

Fan F, Muoya Y, Roman RJ. Cytochrome P450 eicosanoids in hypertension and renal disease. Curr Opin Nephrol Hypertens. 2015;24:37–46. PubMed PMC

Huang H, Morisseau C, Wang JF, Yang T, Falck JR, Hammock BD, Wang MH. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol. 2007;293:F342–F349. PubMed

Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 2010;24:3770–3781. PubMed PMC

Sporková A, Kopkan L, Varcabová A, Husková Z, Hwang SH, Hammock BD, et al. Role of cytochrome P450 metabolites in the regulation of renal function and blood pressure in 2-kidney, 1-clip hypertensive rats. Am J Physiol. 2011;300:R1468–R1475. PubMed PMC

Neckář J, Kopkan L, Husková Z, Kolář F, Papoušek F, Kramer HJ, et al. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-I-ylureido)cyclohexy-loxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci. 2012;122:513–525. PubMed PMC

Honetschlägerová Z, Husková Z, Vaňourková Z, Sporková A, Kramer HJ, Hwang SH, et al. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J Physiol. 2011;589:207–219. PubMed PMC

Varcabová Š, Husková Z, Kramer HJ, Hwang SH, Hammock BD, Imig JD, et al. Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin–angiotensin system. Clin Exp Pharmacol Physiol. 2013;40:273–281. PubMed PMC

Honetschlägerová Z, Sporková A, Kopkan L, Husková Z, Hwang SH, Hammock BD, et al. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2011;29:1590–1601. PubMed PMC

Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M, et al. Altered release of cytochrome P450 metabolites of arachidonic acid in renovascular disease. Hypertension. 2008;51:1379–1385. PubMed PMC

Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci U S A. 1990;87:5893–5897. PubMed PMC

Schuck RN, Theken KN, Edin ML, Caughey M, Bass A, Ellis K, et al. Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis. 2013;227:442–448. PubMed PMC

Bellien J, Iacob M, Remy-Jouet I, Lucas D, Monteil C, Gutierrez L, et al. Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension. Circulation. 2012;125:1266–1275. PubMed

Bellien J, Joannides R. Epoxyeicosatrienoic acid pathway in human health and diseases. J Cardiovasc Pharmacol. 2013;61:188–196. PubMed

Falck JR, Kodela R, Manne R, Atcha R, Puli N, Dubasi N, et al. 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J Med Chem. 2009;52:5069–5075. PubMed PMC

Imig JD, Elmarakby A, Nithipatikom K, Wei S, Capdevila JH, Tuniki RV, et al. Development of epoxyeiocastrienoic acids analogs with in vivo antihypertensive actions. Front Physiol. 2010;1:157. PubMed PMC

Hye Khan MA, Pavlov TS, Christain SV, Neckář J, Staruschenko A, Gauthier KM, et al. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilatation and sodium channel inhibition. Clin Sci. 2014;127:463–474. PubMed PMC

Alánová P, Husková Z, Kopkan L, Sporková A, Jíchová Š, Neckář J, et al. Orally active epoxyeicosatrienoic acid analog does not exhibit anti-hypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. Vascul Pharmacol. 2015;73:45–56. PubMed

Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, et al. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem. 2001;276:36727–36733. PubMed

Husková Z, Vaňourková Z, Erbanová M, Thumová M, Opočenský M, Mullins JJ, et al. Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2010;28:495–509. PubMed

Honetschlägerová Z, Kitada K, Husková Z, Sporková A, Kopkan L, Bürgelová M, et al. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. J Hypertens. 2013;31:321–332. PubMed PMC

Vaňourková Z, Kramer HJ, Husková Z, Vaněčková I, Opočenský M, Čertíková Chábová V, et al. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens. 2006;24:2465–2472. PubMed

Erbanová M, Thumová M, Husková Z, Vaněčková I, Vaňourková Z, Mullins JJ, et al. Impairment of the autoregulation of renal hemodynamics and of the pressure-natriuresis relationship precedes the development of hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2009;27:575–586. PubMed

Sporková A, Jíchová Š, Husková Z, Kopkan L, Nishiyama A, Hwang SH, et al. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: Studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2014;41:1003–1013. PubMed PMC

Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM, Mullins JJ. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal angiotensin II levels of graded severity in Cyp1a1-Ren2 transgenic rats. JRAAS. 2006;7:74–86. PubMed

Peters B, Grisk O, Becher B, Wanka H, Kuttler B, Ludemann J, et al. Dose-dependent titration of prorenin and blood pressure in Cyp1a1-Ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J Hypertens. 2008;26:102–109. PubMed

Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurements in humans and experimental animals. Part 2: Blood pressure measurements in experimental animals. Hypertension. 2005;45:299–310. PubMed

Husková Z, Kramer HJ, Vaňourková Z, Červenka L. Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J Hypertens. 2006;24:517–527. PubMed

Fox J, Guan S, Hymel AA, Navar LG. Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol. 1992;262:F902–F909. PubMed

Červenka L, Bíbová J, Husková Z, Vaňourková Z, Kramer HJ, Herget J, et al. Combined suppression of the intrarenal and circulating vasoconstrictor renin-ACE-ANG II axis and augmentation of the vasodilator ACE2-ANG 1-7-Mas axis attenuates the systemic hypertension in Ren-2 transgenic rats exposed to chronic hypoxia. Physiol Res. 2015;64:11–24. PubMed

Bürgelová M, Vaňourková Z, Thumová M, Dvořák P, Opočenský M, Kramer HJ, et al. Impairment of the angiotensin-converting enzyme 2-angiotensin-(1–7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension. J Hypertens. 2009;27:1988–2000. PubMed

Hampl V, Herget J, Bíbová J, Baňasová A, Husková Z, Vaňourková Z, et al. Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1–7/G-protein-coupled mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia. Physiol Res. 2015;64:25–38. PubMed

Husková Z, Kopkan L, Červenková L, Doleželová Š, Vaňourková Z, Škaroupková P, et al. Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1–7 complex of the renin–angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2016;43:438–449. PubMed

Wang CT, Chin SY, Navar LG. Impairment of pressure-natriuresis and renal autoregulation in ANG II-infused hypertensive rats. Am J Physiol. 2000;279:F319–F325. PubMed

Elased KM, Cunha TS, Marcondes FK, Morris M. Brain angiotensin-converting enzyme 2 in processing angiotensin II in mice. Exp Physiol. 2008;93:665–675. PubMed PMC

Madhun ZT, Goldthwait DA, McKay D, Hopfer U, Douglas JG. An epoxygenase metabolite of arachidonic acid mediates angiotensin II-induced rises in cytosolic calcium in rabbit proximal tubule epithelial cells. J Clin Invest. 1991;88:456–461. PubMed PMC

Sakairi Y, Jacobson HR, Noland DT, Capdevila JH, Falck JR, Breyer MD. 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am J Physiol. 1995;268:F931–F939. PubMed

Sigmon DH, Beierwaltes WH. Renal nitric oxide and angiotensin II interaction in renovascular hypertension. Hypertension. 1993;22:237–242. PubMed

Navar LG, Ichihara A, Chin SY, Imig JD. Nitric oxide–angiotensin II interactions in angiotensin II-dependent hypertension. Acta Physiol Scand. 2000;168:139–147. PubMed

Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol. 2003;284:R893–R912. PubMed

Kawada N, Imai E, Karber A, Welch W, Wilcox CS. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol. 2002;13:2860–2868. PubMed

Kopkan L, Husková Z, Vaňourková Z, Thumová M, Škaroupková P, Červenka L, Majid DSW. Superoxide and its interaction with nitric oxide modulates renal function in prehypertensive Ren-2 transgenic rats. J Hypertens. 2007;25:2257–2265. PubMed

Majid DSW, Kopkan L. Nitric oxide and superoxide interactions in the kidney and their implication in the development of salt-sensitive hypertension. Clin Exp Pharmacol Physiol. 2007;34:946–952. PubMed

Hercule HC, Schunck WH, Gross V, Seringer J, Leung FP, Weldon SM, et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol. 2009;29:54–60. PubMed

Patterson ME, Mullins JJ, Mitchell KD. Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension. Am J Physiol. 2008;294:F205–F211. PubMed

Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin–angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251–287. PubMed

Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK, Giani JF, Nguyen MTX, Riquier-Brison AD, et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest. 2013;123:2011–2023. PubMed PMC

Ferrario CM, Santos RA, Brosnihan KB, Block CH, Schiavone MT, Khosla MC, et al. A hypothesis regarding the function of angiotensin peptides in the brain. Clin Exp Hypertens. 1988;10(Suppl 1):107–121. PubMed

Ferrario CM, Brosnihan KB, Diz DI, Jaiswal N, Khosla MC, Milsted A, et al. Angiotensin-(1–7): a new hormone of the angiotensin system. Hypertension. 1991;18(Suppl 5):126–133. PubMed

Ferrario CM. ACE2: more Ang-(1–7) or less Ang II? Curr Opin Nephrol Hypertens. 2011;20:1–6. PubMed PMC

Impaired renal autoregulation and pressure-natriuresis: any role in the development of heart failure in normotensive and angiotensin II-dependent hypertensive rats?

Inappropriate activation of the renin-angiotensin system improves cardiac tolerance to ischemia/reperfusion injury in rats with late angiotensin II-dependent hypertension

Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation

Increased Endogenous Activity of the Renin-Angiotensin System Reduces Infarct Size in the Rats with Early Angiotensin II-dependent Hypertension which Survive the Acute Ischemia/Reperfusion Injury

Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats

Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats

Epoxyeicosanoids in hypertension

Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats

Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats

20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats

Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension

Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease